<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Health Econ</journal-id><journal-id journal-id-type="iso-abbrev">Health Econ</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Health economics</journal-title></journal-title-group><issn pub-type="ppub">1057-9230</issn><issn pub-type="epub">1099-1050</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10872383</article-id><article-id pub-id-type="pmcid-ver">PMC10872383.319</article-id><article-id pub-id-type="pmcaid">10872383</article-id><article-id pub-id-type="pmcaiid">10872383</article-id><article-id pub-id-type="manuscript-id">NIHMS1943552</article-id><article-id pub-id-type="pmid">37985466</article-id><article-id pub-id-type="doi">10.1002/hec.4779</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1943552</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1943552</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Why Higher Copayments for Opioids Did Not Reduce Use Among Medicare Beneficiaries</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Joyce</surname><given-names initials="G">Geoffrey</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="B">Bo</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kaestner</surname><given-names initials="R">Robert</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>University of Southern California Schaeffer Center for Health Policy and Economics</aff><aff id="A2"><label>2</label>USC School of Pharmacy</aff><aff id="A3"><label>3</label>Harris School of Public Policy, University of Chicago and NBER</aff><author-notes><corresp id="CR1"><bold>Corresponding Author</bold>: Geoffrey Joyce, PhD, Director of Health Policy, USC Schaeffer Center for Health Policy and Economics, Associate Professor and Chair, Department of Pharmaceutical and Health Economics, USC School of Pharmacy, 635 Downey Way, VPD 412D, Los Angeles, CA 90089-3333, <email>gjoyce@usc.edu</email>, 213-821-7958</corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>20</day><month>11</month><year>2023</year></pub-date><volume>33</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">455926</issue-id><fpage>466</fpage><lpage>481</lpage><pub-history><event event-type="nihms-submitted"><date><day>09</day><month>11</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-03-01 00:25:24.073"><day>01</day><month>03</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1943552.pdf"/><abstract id="ABS1"><sec id="S1"><title>Objective.</title><p id="P1">To examine whether higher cost-sharing deterred prescription opioid use.</p></sec><sec id="S2"><title>Data Source.</title><p id="P2">Medicare Part D claims from 2007 to 2016 for a 20% random sample of Medicare enrollees.</p></sec><sec id="S3"><title>Study Design.</title><p id="P3">We obtain estimates of the effect of cost-sharing on prescription opioid use using ordinary least squares and instrumental variables methods. In both, we exploit the variation (change) in cost-sharing within plans over time for a sample of beneficiaries who remain in the same plan. Focusing on changes in cost-sharing within a plan for a constant sample of beneficiaries eliminates potential bias from plan selection and using a constant set of weights derived from use in year (t) eliminates changes in the cost-sharing indexes due to (endogenous) consumer choice in year (t+1).</p></sec><sec id="S4"><title>Principal Findings.</title><p id="P4">Part D plans adopted benefit changes designed to reduce opioid use, including moving opioids to higher cost-sharing tiers. Increasing plan copayments for hydrocodone or oxycodone was associated with reductions in plan-paid claims and offsetting increases in cash claims. Widespread availability of low-cost generics combined with the anti-clawback provision in Part D mediated the effect of higher cost sharing to curb opioid use. As plans moved generic opioids to higher cost-sharing tiers, beneficiaries simply paid cash prices and aggregate use remained largely unchanged.</p></sec><sec id="S5"><title>Conclusions.</title><p id="P5">The anti-clawback provision in Part D, intended to protect beneficiaries from price gouging, limited plans&#8217; ability to constrain opioid use through typical demand-side measures such as increased cost-sharing.</p></sec></abstract><kwd-group><kwd>Medicare Part D</kwd><kwd>Opioids</kwd><kwd>Prescription drugs</kwd><kwd>clawbacks</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>